Federal Register / Vol. 88, No. 222 / Monday, November 20, 2023 / Notices 80733 

Regulations’’). At the conclusion of the 

Exclusion Period, Respondent agrees to 

have her research supervised for a 

period of two (2) years (the 

‘‘Supervision Period’’). During the 

Supervision Period, prior to the 

submission of an application for PHS 

support for a research project on which 

Respondent’s participation is proposed 

and prior to Respondent’s participation 

in any capacity in PHS-supported 

research, Respondent will submit a plan 

for supervision of Respondent’s duties 

to ORI for approval. The supervision 

plan must be designed to ensure the 

integrity of Respondent’s research. 

Respondent will not participate in any 

PHS-supported research until such a 

supervision plan is approved by ORI. 

Respondent will comply with the 

agreed-upon supervision plan. 

(2) During the Exclusion Period, 

Respondent will not apply for, permit 

her name to be used on an application 

for, receive, or be supported by funds of 

the United States Government and its 

agencies made available through 

contracts, subcontracts, or covered 

transactions. 

(3) During the Supervision Period, the 

requirements for Respondent’s 

supervision plan are as follows: 

i. A committee of 2–3 senior faculty 

members at the institution including 

Respondent’s supervisor or 

collaborators will provide oversight and 

guidance. The committee will review 

primary data from Respondent’s 

laboratory on a quarterly basis and 

submit a report to ORI at six (6) month 

intervals setting forth the committee 

meeting dates and Respondent’s 

compliance with appropriate research 

standards and confirming the integrity 

of Respondent’s research. 

ii. The committee will conduct an 

advance review of each application for 

PHS funds, or report, manuscript, or 

abstract involving PHS-supported 

research in which Respondent is 

involved. The review will include a 

discussion with Respondent of the 

primary data represented in those 

documents and will include a 

certification to ORI that the data 

presented in the proposed application, 

report, manuscript, or abstract are 

supported by the research record. 

(4) During the Supervision Period, 

Respondent will ensure that any 

institution employing her submits, in 

conjunction with each application for 

PHS funds, or report, manuscript, or 

abstract involving PHS-supported 

research in which Respondent is 

involved, a certification to ORI that the 

data provided by Respondent are based 

on actual experiments or are otherwise 

legitimately derived and that the data, 

procedures, and methodology are 

accurately reported and not plagiarized 

in the application, report, manuscript, 

or abstract. 

(5) If no supervision plan is provided 

to ORI, Respondent will provide 

certification to ORI at the conclusion of 

the Supervision Period that her 

participation was not proposed on a 

research project for which an 

application for PHS support was 

submitted and that she has not 

participated in any capacity in PHSsupported research. 

(6) During the Exclusion and 

Supervision Periods, Respondent will 

exclude herself voluntarily from serving 

in any advisory or consultant capacity 

to PHS including, but not limited to, 

service on any PHS advisory committee, 

board, and/or peer review committee. 

Dated: November 15, 2023. 

Sheila Garrity, 

Director, Office of Research Integrity, Office 

of the Assistant Secretary for Health. 

[FR Doc. 2023–25603 Filed 11–17–23; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SEP–3: NCI 

Clinical and Translational Cancer Research. 

Date: February 21–22, 2024. 

Time: 9:30 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute Shady 

Grove, 9609 Medical Center Drive, Room 

7W612, Rockville, Maryland 20850, (Virtual 

Meeting). 

Contact Person: Prashant Sharma, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W612, Rockville, 

Maryland 20850, 240–275–6351, 

prashant.sharma@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: November 15, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–25619 Filed 11–17–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Coast Guard 

[Docket No. USCG–2023–0830] 

National Merchant Mariner Medical 

Advisory Committee; December 2023 

Virtual Meeting 

AGENCY: United States Coast Guard, 

Department of Homeland Security. 

ACTION: Notice of open Federal advisory 

committee virtual meeting. 

SUMMARY: The National Merchant 

Mariner Medical Advisory Committee 

(Committee) will conduct a virtual 

meeting to discuss matters relating to 

medical certification determinations for 

issuance of licenses, certificates of 

registry, and merchant mariners’ 

documents, medical standards, and 

guidelines for the physical 

qualifications of operators of 

commercial vessels, medical examiner 

education, and medical research. The 

virtual meeting will be open to the 

public. 

DATES: Meeting: The Committee will 

meet virtually on Tuesday, December 

19, 2023, from noon until 3:00 p.m. 

Eastern Standard Time, (EST). The 

virtual meeting may adjourn early if the 

Committee has completed its business. 

Comments and supporting 

documentation: To ensure your 

comments are received by Committee 

members before the virtual meeting, 

submit your written comments no later 

than December 12, 2023. 

ADDRESSES: To join the virtual meeting 

or to request special accommodations, 

contact the individual listed in the FOR

FURTHER INFORMATION CONTACT section 

no later than 1 p.m. EST on December 

12, 2023, to obtain the needed 

information. 


ddrumheller on DSK120RN23PROD with NOTICES1
80734 Federal Register / Vol. 88, No. 222 / Monday, November 20, 2023 / Notices 

The Committee is committed to 

ensuring all participants have equal 

access regardless of disability status. If 

you require reasonable accommodation 

due to a disability to fully participate, 

please email Ms. Pamela Moore 

pamela.j.moore@uscg.mil or call 202– 

372–1361 as soon as possible. 

Instructions: You are free to submit 

comments at any time, including orally 

at the virtual meeting as time permits, 

but if you want the Committee members 

to review your comment before the 

virtual meeting, please submit your 

comments no later than December 12, 

2023. We are particularly interested in 

comments regarding the topics in the 

‘‘Agenda’’ section below. We encourage 

you to submit comments through the 

Federal Decision Making Portal at 

https://www.regulations.gov. To do so, 

go to https://www.regulations.gov, type 

USCG–2023–0830 in the search box and 

click ‘‘Search.’’ Next, look for this 

document in the Search Results column, 

and click on it. If your material cannot 

be submitted using https:// 

www.regulations.gov, email the 

individual in the FOR FURTHER

INFORMATION CONTACT section of this 

document for alternate instructions. You 

must include the docket number USCG– 

2023–0830. Comments received will be 

posted without alteration at https:// 

www.regulations.gov. including any 

personal information provided. You 

may wish to review the Privacy and 

Security Notice, found via link on the 

homepage https://www.regulations.gov. 

For more about privacy and submissions 

in response to this document, see DHS’s 

eRulemaking System of Records notice 

(85 FR 14226, March 11, 2020). If you 

encounter technical difficulties with 

comment submission, contact the 

individual listed in the FOR FURTHER

INFORMATION CONTACT section of this 

notice. 

Docket Search: Documents mentioned 

in this notice as being available in the 

docket, and all public comments, will 

be in our online docket at https:// 

www.regulations.gov and can be viewed 

by following that website’s instructions. 

Additionally, if you go to the online 

docket and sign-up for email alerts, you 

will be notified when comments are 

posted. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Pamela Moore, Alternate Designated 

Federal Officer of the National Merchant 

Mariner Medical Advisory Committee, 

telephone 202–372–1361 or email 

pamela.j.moore@uscg.mil. 

SUPPLEMENTARY INFORMATION: Notice of 

this meeting is in compliance with the 

Federal Advisory Committee Act (Pub. 

L. 117–286, 5 U.S.C., ch. 10). The 

Committee is authorized by section 601 

of the Frank LoBiondo Coast Guard 

Authorization Act of 2018 (Pub. L. 115– 

282, 132 Stat. 4192), and is codified in 

46 U.S.C. 15104. The Committee 

operates under the provisions of the 

Federal Advisory Committee Act and 46 

U.S.C 15109. The Committee advises the 

Secretary of Homeland Security through 

the Commandant of the United States 

Coast Guard on matters relating to: (a) 

medical certification determinations for 

issuance of licenses, certificates of 

registry, and merchant mariners’ 

documents; (b) medical standards and 

guidelines for the physical 

qualifications of operators of 

commercial vessels; (c) medical 

examiner education; and (d) medical 

research. 

AGENDA: The National Merchant Mariner 

Medical Advisory Committee will meet 

on Tuesday, December 19, 2023. 

The agenda for the December 19, 

2023, meeting is as follows: 

(1) Introduction. 

(2) Designated Federal Officer 

Remarks. 

(3) Roll call of Committee members. 

(4) Adoption of the Agenda. 

(5) Acceptance of Minutes from 

Committee Meeting 5. 

(6) U.S. Coast Guard Presentations: 

(a) 2023 Report on Recommendations 

to the U.S. Coast Guard from the 

National Merchant Mariner Medical 

Advisory Committee; 

(b) Presentation of New Merchant 

Mariner Credential. 

(7) Public comment period. 

(8) Closing remarks. 

(9) Adjournment of meeting. 

A copy of all meeting documentation 

will be available at https://homeport.

uscg.mil/missions/federal-advisorycommittees/national-merchant-marinermedical-advisory-committee-(nmedmac) 

no later than December 12, 2023. 

Alternatively, you may contact the 

individual noted in the FOR FURTHER

INFORMATION CONTACT section above. 

During the December 19, 2023 

meeting, a public comment period will 

be held immediately after the U.S. Coast 

Guard Presentations, at approximately 

2:30 p.m. EST. Public comments will be 

limited to 3 minutes per speaker and 

limited to one comment per person. 

Please note that the public comment 

period will end following the last call 

for comments. 

Please contact the individual listed in 

the FOR FURTHER INFORMATION CONTACT

section to register as a speaker. 

Dated: November 15, 2023. 

Jeffrey G. Lantz, 

Director of Commercial Regulations and 

Standards. 

[FR Doc. 2023–25618 Filed 11–17–23; 8:45 am] 

BILLING CODE 9110–04–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID FEMA–2023–0002; Internal 

Agency Docket No. FEMA–B–2387] 

Proposed Flood Hazard 

Determinations 

AGENCY: Federal Emergency 

Management Agency, Department of 

Homeland Security. 

ACTION: Notice. 

SUMMARY: Comments are requested on 

proposed flood hazard determinations, 

which may include additions or 

modifications of any Base Flood 

Elevation (BFE), base flood depth, 

Special Flood Hazard Area (SFHA) 

boundary or zone designation, or 

regulatory floodway on the Flood 

Insurance Rate Maps (FIRMs), and 

where applicable, in the supporting 

Flood Insurance Study (FIS) reports for 

the communities listed in the table 

below. The purpose of this notice is to 

seek general information and comment 

regarding the preliminary FIRM, and 

where applicable, the FIS report that the 

Federal Emergency Management Agency 

(FEMA) has provided to the affected 

communities. The FIRM and FIS report 

are the basis of the floodplain 

management measures that the 

community is required either to adopt 

or to show evidence of having in effect 

in order to qualify or remain qualified 

for participation in the National Flood 

Insurance Program (NFIP). 

DATES: Comments are to be submitted 

on or before February 20, 2024. 

ADDRESSES: The Preliminary FIRM, and 

where applicable, the FIS report for 

each community are available for 

inspection at both the online location 

https://hazards.fema.gov/femaportal/ 

prelimdownload and the respective 

Community Map Repository address 

listed in the tables below. Additionally, 

the current effective FIRM and FIS 

report for each community are 

accessible online through the FEMA 

Map Service Center at https://

msc.fema.gov for comparison. 

You may submit comments, identified 

by Docket No. FEMA–B–2387, to Rick 

Sacbibit, Chief, Engineering Services 

Branch, Federal Insurance and 


ddrumheller on DSK120RN23PROD with NOTICES1